RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDAÂ Phase II Study for IBSD

Topline results are expected in the third quarter of 2017 The randomized doubleblind placebocontrolled Phase II study is evaluating the safety and efficacy of BEKINDAÂ RHB102 12 mg in 127 U.S. patients with diarrheapredominant irritable bowel syndrome IBSD...